Does continuous glucose monitoring have enough long-term human evidence?

Who benefits most from CGM, and by how much?

The strongest evidence shows that people with type 2 diabetes on basal insulin (without mealtime insulin) get a clear, meaningful benefit. In a randomized trial of 175 adults with poorly controlled type 2 diabetes, those using CGM for 8 months spent 59% of their time in the target blood sugar range (70-180 mg/dL), compared to just 43% for those using standard fingerstick monitoring—a 15 percentage point improvement [1]. Their average blood sugar also dropped significantly more (HbA1c 8.0% vs. 8.4%) [1]. This is a practical, real-world gain for a large group of patients.

For children and teens with type 1 diabetes, the benefit depends heavily on how consistently they wear the device. A randomized trial in 144 youth starting insulin pump therapy found that starting CGM at the same time as the pump led to 62 more hours of CGM use per month after 6 months, compared to delaying CGM [2]. Critically, for every 100 hours of CGM use per 28-day period, HbA1c was 0.39% lower [2]. This means the device only helps if it's actually worn, and early adoption can build that habit.

Even in extreme situations, CGM proves its worth. After the 2023 Kahramanmaraş earthquake in Turkey, children with type 1 diabetes who had access to CGM actually improved their HbA1c (from 8.9% to 8.6%), while those without CGM saw their control worsen [6]. The effect was strongest in adolescents over 12 years old [6]. This shows CGM can buffer against the chaos of disrupted routines and stress.

What are the caveats? Where does the evidence fall short?

The evidence is not uniformly positive. In a randomized trial of 100 older adults in long-term care facilities (average age 75), using real-time CGM to guide insulin adjustments did not improve time in range compared to standard fingerstick checks over about 17 days [4]. Both groups improved similarly, suggesting that in very controlled, supervised settings, the added value of CGM may be smaller [4]. This is an important reminder that CGM's benefit depends on the context—it shines when it enables proactive, at-home adjustments, not when care is already tightly managed by staff.

Another key caveat: short-term CGM data can be misleading. A study analyzing 90 days of CGM data from 329 people with type 1 diabetes found that using only 10-14 days of data to estimate long-term control introduced a bias of 10% to 47% [5]. Even 30 days of data still had a bias of 5% to 26% [5]. This means that a single 10-day CGM wear period might not accurately reflect a person's true average glucose over three months, especially for detecting hypoglycemia. Clinicians and researchers should use longer monitoring periods when possible.

The longest-term evidence—linking CGM metrics to hard outcomes like death—is still very new. One real-world study of 2,752 veterans (65% with type 2 diabetes) found that CGM-derived metrics like time in range and glucose variability predicted all-cause mortality over 5 years, even after adjusting for HbA1c [9]. This is promising, but it's a single observational study, not a randomized trial. It suggests CGM data may capture risk that HbA1c misses, but we don't yet have randomized trials proving that using CGM to improve these metrics actually reduces mortality.

Does the evidence support long-term, everyday use of CGM?

Yes, for the right patients. The studies here cover use from 10 days up to several years, and the pattern is consistent: CGM improves glucose control and reduces dangerous highs and lows. A consensus statement from major diabetes organizations (including the American Diabetes Association and the European Association for the Study of Diabetes) now recommends CGM-derived metrics—like time in range, time above range, and time below range—as standard endpoints in clinical trials [7]. This reflects a broad expert agreement that CGM provides valuable information beyond HbA1c.

Newer technologies are also being tested for long-term use. A pilot study of an implantable CGM (Eclipse 3) in 8 adults with type 1 diabetes showed it was safe and well-tolerated for up to 10 months, with stable accuracy (median MARD of 12.4%) and no serious adverse events [3]. Another study tested a novel semiconductor-based CGM+ system over multiple days and found it tracked glucose accurately during daily activities like sleeping, eating, and exercising [8]. These are early but promising steps toward devices that could be worn for months at a time.

The bottom line: the evidence for CGM's effectiveness in improving day-to-day glucose control is strong and comes from multiple randomized trials. The evidence for long-term benefits on hard outcomes like mortality is emerging but not yet definitive. For most people with diabetes who are on insulin or have trouble controlling their blood sugar, the existing data supports using CGM as a tool to improve control and reduce risk.

About These Sources

This answer is built on 9 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 4 in Q1 journals, collectively cited 1,095 times — selected as the most relevant from 11 studies that passed quality screening, drawn from 80 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions